Dark

BTX
BlackRock Technology and Private Equity Term Trust
stock NYSE

At Close

May 22, 2025 3:59:30 PM EDT

6.73USD+1.279%(+0.09)470,003

6.72Bid 6.73Ask 0.01Spread

Pre-market

May 19, 2025 8:52:30 AM EDT

6.78USD+2.032%(+0.14)0

After-hours

May 19, 2025 4:04:30 PM EDT

6.82USD-0.146%(-0.01)0

OverviewHistoricalExchangesShortsNews

Jan 20, 2022

07:39AM EST Brooklyn ImmunoTherapeutics Welcomes Erin Enright And Heather Redman To Board RTTNews

07:30AM EST Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (Brooklyn), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of two new members of the Companys Board of Directors. GlobeNewswire Inc

Jan 13, 2022

11:47AM EST Brooklyn ImmunoTherapeutics Announces 18 New Patents Were Issued And 17 Were Filed In 2021 Benzinga

08:30AM EST Brooklyn ImmunoTherapeutics Provides Update on Regenerative GlobeNewswire Inc

Jan 5, 2022

06:12AM EST Brooklyn Immunotherapeutics Said on January 3, 2022, Co Completed Reduction in Force Comprising Eight Employees, 53% of Workforce; Co Estimates It Will Incur About $0.5M for Severance and Termination-related Costs Benzinga

Dec 29, 2021

07:05AM EST Cantor Fitzgerald Initiates Coverage On Brooklyn with Overweight Rating, Announces Price Target of $9 Benzinga

Dec 17, 2021

08:08AM EST Brooklyn ImmunoTherapeutics Added To ICE Biotechnology Index Effective Dec. 20, 2021 Benzinga

08:00AM EST Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (Brooklyn), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces that Brooklyn has been added to the ICE Biotechnology Index (NYSE:ICEBIO) following the December 20, 2021 reconstitution. GlobeNewswire Inc

Dec 14, 2021

08:47AM EST Brooklyn ImmunoTherapeutics Named To Nasdaq Biotechnology Index Benzinga

08:47AM EST Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (Brooklyn), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces that Brooklyn has been named to be part of the Nasdaq Biotechnology Index (Nasdaq:NBI), effective December 20, 2021. GlobeNewswire Inc

Dec 9, 2021

09:40PM EST From Benzinga's Global Small Cap Conference: Brooklyn ImmunoTherapeutics President & CEO, Dr. Howard J. Federoff, M.D., Ph.D. Begins Presenting Benzinga

Dec 2, 2021

08:00AM EST Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (Brooklyn), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that President and CEO Howard Federoff, M.D., Ph.D. is scheduled to present at the following virtual conferences: GlobeNewswire Inc

Nov 29, 2021

08:00AM EST Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (Brooklyn), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of Susan McClatchey as Vice President, Head of Quality. GlobeNewswire Inc

Nov 19, 2021

06:04AM EST Brooklyn ImmunoTherapeutics Reports Filing Of Registration Statement For Offering Of Shares Issued In Novellus Deal Benzinga

06:00AM EST Brooklyn ImmunoTherapeutics Announces Filing of Registration GlobeNewswire Inc

Nov 9, 2021

06:29PM EST Brooklyn ImmunoTherapeutics Reports Q3 2021 Operating Expenses $86.3M Benzinga

Oct 14, 2021

04:15PM EDT Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq GlobeNewswire Inc

Oct 6, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2021 Benzinga

08:22AM EDT Maxim Group Initiates Coverage On Brooklyn with Buy Rating, Announces Price Target of $20 Benzinga

Sep 23, 2021

04:30PM EDT Brooklyn ImmunoTherapeutics ReportsInducement Grants GlobeNewswire Inc

Sep 22, 2021

10:08AM EDT Brooklyn ImmunoTherapeutics Names Roger Sidhu Chief Medical Officer Benzinga

10:07AM EDT Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (Brooklyn), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Roger Sidhu, M.D. as its Chief Medical Officer, effective September20, 2021. GlobeNewswire Inc

Sep 21, 2021

08:30AM EDT Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder GlobeNewswire Inc

Sep 15, 2021

08:16AM EDT Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 PR Newswire

Sep 13, 2021

08:00AM EDT Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (Brooklyn), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that management will host a shareholder update conference call on Monday, September 20, 2021, at 4:30 p.m. ET. GlobeNewswire Inc

Sep 9, 2021

08:30AM EDT Brooklyn ImmunoTherapeutics to Participate in Grand Opening of GlobeNewswire Inc

Aug 20, 2021

04:15PM EDT Brooklyn ImmunoTherapeutics Announces Adjournment of Annual GlobeNewswire Inc

08:30AM EDT Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder GlobeNewswire Inc

Aug 16, 2021

04:15PM EDT Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (Brooklyn), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that it will host a shareholder update conference call on Thursday, August 19, 2021, at 4:30 p.m. ET. GlobeNewswire Inc

07:13AM EDT Brooklyn Q2 EPS $(0.24) Benzinga

07:00AM EDT Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (Brooklyn), a biopharmaceutical company focused on exploring the role that gene editing/cell and cytokine therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced financial results for the quarter ended June 30, 2021. GlobeNewswire Inc

Aug 13, 2021

02:22PM EDT Brooklyn ImmunoTherapeutics to Present at the SNN Virtual Investor GlobeNewswire Inc

Jul 23, 2021

04:30PM EDT Brooklyn Immuno Reports Inducement Grants GlobeNewswire Inc

Jul 19, 2021

08:00AM EDT Acquisition Advances Transformation Into Platform Company Focused on Cell, Gene Editing and Cytokine Therapy GlobeNewswire Inc

Jul 13, 2021

08:17AM EDT Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (Brooklyn), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Jay Sial as its Chief Administrative Officer, effective July 15, 2021. GlobeNewswire Inc

Jul 12, 2021

08:17AM EDT Brooklyn ImmunoTherapeutics to Present at the Access to Giving GlobeNewswire Inc

Jul 6, 2021

05:57PM EDT Brooklyn ImmunoTherapeutics Reports Inducement Grants GlobeNewswire Inc

Jun 28, 2021

11:41AM EDT Brooklyn Option Alert: Jul 16 $30 Calls Sweep (4) near the Ask: 200 @ $1.7 vs 651 OI; Earnings 7/9 Before Open [est] Ref=$22.553 Benzinga

Jun 14, 2021

12:24PM EDT Brooklyn ImmunoTherapeutics Stock Rises After Novellus Therapeutics Buyout Deal Benzinga

07:42AM EDT Brooklyn ImmunoTherapeutics Executes LoI To Acquire Novellus Therapeutics RTTNews

07:33AM EDT Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics for $17.4M in Cash and $107.6M in BTX Stock Benzinga

07:30AM EDT Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire GlobeNewswire Inc

Jun 9, 2021

07:32AM EDT Brooklyn ImmunoTherapeutics Set to Join Russell 3000 Index Benzinga

Jun 8, 2021

07:40AM EDT Brooklyn ImmunoTherapeutics Names Kevin D'Amour As Chief Scientific Officer RTTNews

07:30AM EDT Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic disorders, today announced the appointment of Kevin A. DAmour, Ph.D. as its Chief Scientific Officer. GlobeNewswire Inc

Jun 2, 2021

08:00AM EDT Brooklyn ImmunoTherapeutics Establishes Research and Development GlobeNewswire Inc

May 26, 2021

05:25PM EDT Brooklyn ImmunoTherapeutics Says Reserved 1.5M Shares Of Common Stock For Issuance Pursuant To Equity Awards Granted Under The Inducement Plan Benzinga

02:03PM EDT Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company's Future During May 25, 2021 Shareholder Update Call Business Wire

May 24, 2021

03:28PM EDT Brooklyn ImmunoTherapeutics Strengthens Investment In Licensed MRNA Technology Platform With $20 Mln Financing RTTNews

May 21, 2021

07:35AM EDT Brooklyn ImmunoTherapeutics Appoints Michael Andreeff To Scientific Advisory Board RTTNews

07:30AM EDT Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc. Business Wire

May 18, 2021

07:30AM EDT Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET Business Wire

May 11, 2021

12:56PM EDT Publication In Breast Cancer Research Indicate Brooklyn ImmunoTherapeutics' IRX-2 May Hold Promise In Early-Stage Breast Cancer Benzinga

07:45AM EDT Brooklyn ImmunoTherapeutics Announces Publication Of Results Of IRX-2 Monotherapy In Early Stage Breast Cancer RTTNews

07:37AM EDT Brooklyn ImmunoTherapeutics Highlights Publication Of Results Of IRX-2 Monotherapy In Early Stage Breast Cancer In Breast Cancer Research Benzinga

07:30AM EDT Brooklyn ImmunoTherapeutics Announces Publication of Results of IRX-2 Monotherapy in Early Stage Breast Cancer in Breast Cancer Research Business Wire

May 7, 2021

07:30AM EDT Erich Mohr, Ph.D., to Join the Board of Directors of Brooklyn ImmunoTherapeutics Business Wire

May 3, 2021

02:40PM EDT Mid-Afternoon Market Update: Crude Oil Rises 1.5%; AVROBIO Shares Plummet Benzinga

12:13PM EDT Mid-Day Market Update: Nasdaq Drops 50 Points; Ocugen Shares Spike Higher Benzinga

11:23AM EDT Mid-Morning Market Update: Markets Open Higher; Este Lauder Reports Mixed Q3 Results Benzinga

05:43AM EDT Shares of Brooklyn Immunotherapeutics +58% Premarket; Nicholas Jason Singer DIsclosed a 9%+ Stake in a 13G Filing on Friday; Co Also Reported Purchase Agreement with Lincoln Park Capital Benzinga

Apr 30, 2021

04:21PM EDT Brooklyn ImmunoTherapeutics On Apr. 26 Entered Purchase Agreement With Lincoln Park Capital Fund Under Which Co. May Sell Up To $200M Of Common Stock To Lincoln Park Benzinga

04:10PM EDT Nicholas Jason Singer Discloses 9.13% Passive Stake In Brooklyn ImmunoTherapeutics, Inc. Benzinga

Apr 29, 2021

07:56AM EDT Brooklyn Acquires License For MRNA Technology Platform To Develop Genetically Edited Cells To Treat Multiple Cancers RTTNews

07:45AM EDT Brooklyn ImmunoTherapeutics Acquires License For mRNA Technology Platform Of Factor Bioscience Limited And Novellus Therapeutics Limited; Financial Details Not Disclosed Benzinga

07:30AM EDT Brooklyn ImmunoTherapeutics Acquires License for mRNA Technology Platform to Develop Genetically Edited Cells to Treat Multiple Cancers, Blood and Other Disorders Business Wire

Apr 26, 2021

07:30AM EDT Matthew During, M.D., Ph.D. to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics Business Wire

Apr 23, 2021

10:22AM EDT Mid-Morning Market Update: Markets Rise; Honeywell Beats Q1 Estimates Benzinga

Apr 19, 2021

04:10PM EDT Brooklyn ImmunoTherapeutics Reports Inducement Grants Business Wire

Apr 16, 2021

10:07AM EDT Mid-Morning Market Update: Markets Mostly Higher; Morgan Stanley Beats Q1 Expectations Benzinga

Apr 15, 2021

04:17PM EDT Brooklyn ImmunoTherapeutics Pays $1M Towards Acquisition of License for mRNA Technology Platform to Develop Genetically Edited Cells for Multiple Cancers and Blood Disorders Benzinga

04:10PM EDT Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License for mRNA Technology Platform to Develop Genetically Edited Cells for Multiple Cancers and Blood Disorders Business Wire

08:00AM EDT Dennis H. Langer, M.D., J.D. to Join the Board of Directors of Brooklyn ImmunoTherapeutics, Inc. Business Wire

Apr 6, 2021

02:51PM EDT Mid-Afternoon Market Update: Dow Falls 50 Points; Scienjoy Shares Spike Higher Benzinga

12:33PM EDT Mid-Day Market Update: Crude Oil Rises Over 2%; Scholar Rock Shares Plunge Benzinga

10:24AM EDT Mid-Morning Market Update: Markets Edge Higher; Paychex Profit Tops Views Benzinga

08:13AM EDT Brooklyn ImmunoTherapeutics Names Howard Federoff CEO Benzinga

08:08AM EDT Brooklyn ImmunoTherapeutics Names Howard Federoff As CEO And President And A Director As Of April 16 RTTNews

08:00AM EDT Howard J. Federoff, MD, PhD Appointed Chief Executive Officer of Brooklyn ImmunoTherapeutics, Inc. Business Wire

05:51AM EDT Brooklyn ImmunoTherapeutics Shares Rise 75% Premarket; Multiple Form 3 Filings Late Monday Show New Stakes by Insiders Benzinga

Mar 25, 2021

05:31PM EDT Brooklyn ImmunoTherapeutics Completes Reverse Merger With NTN Buzztime RTTNews